Trial · NCT00218062
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cocaine Use as Assessed by the Treatment Effectiveness Score (TES), Which is the Total Number of Cocaine-negative Urines During Treatment | D-Amphetamine 60mg + Therapy | 9.25 | Standard Deviation 13.45 | number of cocaine negative urines | |
| Cocaine Use as Assessed by the Treatment Effectiveness Score (TES), Which is the Total Number of Cocaine-negative Urines During Treatment | Modafinil 400mg + Therapy | 6.09 | Standard Deviation 8.12 | number of cocaine negative urines | |
| Cocaine Use as Assessed by the Treatment Effectiveness Score (TES), Which is the Total Number of Cocaine-negative Urines During Treatment | Modafinil 200mg + D-Amphetamine 30mg + Therapy | 6 | Standard Deviation 7.73 | number of cocaine negative urines | |
| Cocaine Use as Assessed by the Treatment Effectiveness Score (TES), Which is the Total Number of Cocaine-negative Urines During Treatment | Placebo + Therapy | 4.91 | Standard Deviation 7.56 | number of cocaine negative urines | |
| Retention as Indicated by the Number of Participants Who Completed 16 Weeks of Treatment | D-Amphetamine 60mg + Therapy | 7 | participants | ||
| Retention as Indicated by the Number of Participants Who Completed 16 Weeks of Treatment | Modafinil 400mg + Therapy | 4 | participants | ||
| Retention as Indicated by the Number of Participants Who Completed 16 Weeks of Treatment | Modafinil 200mg + D-Amphetamine 30mg + Therapy | 3 | participants | ||
| Retention as Indicated by the Number of Participants Who Completed 16 Weeks of Treatment | Placebo + Therapy | 3 | participants | ||
| Retention as Indicated by the Number of Participants Who Remained in the Study | D-Amphetamine 60mg + Therapy | 7 | participants | ||
| Retention as Indicated by the Number of Participants Who Remained in the Study | Modafinil 400mg + Therapy | 4 | participants | ||
| Retention as Indicated by the Number of Participants Who Remained in the Study | Modafinil 200mg + D-Amphetamine 30mg + Therapy | 3 | participants | ||
| Retention as Indicated by the Number of Participants Who Remained in the Study | Placebo + Therapy | 3 | participants | ||
| Medication Compliance as Indicated by Percentage of Pills Taken According to Self-report | D-Amphetamine 60mg + Therapy | 80.2 | percentage of pills taken | ||
| Medication Compliance as Indicated by Percentage of Pills Taken According to Self-report | Modafinil 400mg + Therapy | 34.5 | percentage of pills taken | ||
| Medication Compliance as Indicated by Percentage of Pills Taken According to Self-report | Modafinil 200mg + D-Amphetamine 30mg + Therapy | 65.8 | percentage of pills taken | ||
| Medication Compliance as Indicated by Percentage of Pills Taken According to Self-report | Placebo + Therapy | 73.2 | percentage of pills taken | ||
| Medication Compliance as Indicated by Percentage of Riboflavin-positive Urine Samples | D-Amphetamine 60mg + Therapy | 67.1 | % of riboflavin-positive urine samples | ||
| Medication Compliance as Indicated by Percentage of Riboflavin-positive Urine Samples | Modafinil 400mg + Therapy | 70 | % of riboflavin-positive urine samples | ||
| Medication Compliance as Indicated by Percentage of Riboflavin-positive Urine Samples | Modafinil 200mg + D-Amphetamine 30mg + Therapy | 76.8 | % of riboflavin-positive urine samples | ||
| Medication Compliance as Indicated by Percentage of Riboflavin-positive Urine Samples | Placebo + Therapy | 66.7 | % of riboflavin-positive urine samples |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00218062/results